To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer
31-Dec-2001: Abgenix, Inc. (Nasdaq:ABGX - news) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with colorectal cancer. ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. This clinical trial, the third Phase II study of ABX-EGF, is designed to assess the safety and efficacy of ABX-EGF as monotherapy in patients with metastatic colorectal cancer who have previously failed chemotherapy. ABX-EGF is being developed in collaboration with Immunex Corporation.
This multi-center, open-label Phase II study will enroll up to 100 patients. Patients will receive intravenous infusions of 2.5 mg/kg of ABX-EGF weekly over an 8-week treatment cycle, for up to 6 cycles.
``We are pleased to advance our clinical oncology program with the start of this third Phase II trial for ABX-EGF,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``Our goal is to provide effective, antibody-based therapeutic options for cancer patients.''
Preliminary results of an ongoing Phase I clinical trial of ABX-EGF show that it is well tolerated and shows biological activity at low doses. Thus far, three patients in the Phase I study have achieved stable disease/minor response. Other Phase II studies of ABX-EGF in kidney cancer and non-small cell lung cancer are currently ongoing.
- 1Gummy bears under antiparticle fire
- 2Merck Obtains US Antitrust Clearance for Acquisition of Sigma-Aldrich
- 3Nanowire clothing could keep people warm - without heating everything else
- 4Perovskites provide big boost to silicon solar cells, Stanford study finds
- 5REACH 2018 Roadmap
- 6A qubit candidate shines brighter
- 7Clariant acquires Aerochem AB
- 8Additional Member to ZEISS Executive Board
- 9Dutch technology reclaims humic acid at drinking water plants
- 10Waterloo chemist one step closer to a new generation of electric car battery
- Printable luminous particles enable cost-effective, large and curved luminou ...
- Eindhoven researchers observe shell growth thanks to 'ion sponge'
- Exotic, gigantic molecules fit inside each other like Russian nesting dolls
- Is glass a true solid?
- Scientists 'bend' elastic waves with new metamaterials that could have comme ...